Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 7, 2004, Pages 1135-1141

  Carmen Carrasco, M ^a   Vicens, Paloma ^b   Vidal, Jose ^a   Redolat, Rosa ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Dept Psicol Facultat C Spain ^*  (Spain)

Author keywords

Anxiety; Bupropion; Elevated plus maze; Locomotor activity; Male mice; NMRI

Indexed keywords

AMFEBUTAMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR; BODY POSTURE; CONTROLLED STUDY; EMOTIONALITY; ETHOLOGY; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; MOUSE; NONHUMAN; SENSITIVITY ANALYSIS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BEHAVIOR, ANIMAL; BUPROPION; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY;

EID: 10944230860     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.06.005     Document Type: Article

References (47)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th Edition 1994 DSM-IV Washington, DC
2. J.A. Ascher, J.O. Cole, J.N. Colin, J.P. Feighner, R.M. Ferris, H.C. Fibiger, R.N. Golden, P. Martin, W.Z. Potter, E. Richelson, and F. Sulser Bupropion: a review of its mechanism of antidepressant activity J. Clin. Psychiatry 56 1995 395 401
3. D.J.K. Balfour The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion IJCP 55 2001 53 57
4. D.M. Barros, L.A. Izquierdo, J.H. Medina, and I. Izquierdo Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats Behav. Pharmacol. 13 2002 215 220
5. M. Bourin, M.C. Colombel, J.P. Redrobe, J. Nizard, M. Hascoët, and G.B. Baker Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages Prog. Neuro-Psychopharmacol. Biol. Psychiatry 22 1998 343 351
6. B.R. Cooper, T.J. Hester, and R.A. Maxwell Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo J. Pharmacol. Exp. Ther. 215 1980 127 134
7. J.F. Cryan, A.W. Bruijnzeel, K.L. Skjei, and A. Markou Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat Psychopharmacology 168 2003 347 358
8. J. Dong, and P. Blier Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment Psychopharmacology 155 2001 52 57
9. N.P. Emmanuel, O. Brawman-Mintzer, W.A. Morton, S.W. Book, M.R. Johnson, J.P. Lorberbaum, J.C. Ballenger, and R.B. Lydiard Bupropion-SR in treatment of social phobia Depress. Anxiety 12 2000 111 113
10. R.M. Ferris, B.R. Cooper, and R.A. Maxwell Studies of bupropion's mechanism of antidepressant activity J. Clin. Psychiatry 44 1983 74 78
11. S.E. File, S. Cheeta, and P.J. Kenny Neurobiological mechanisms by which nicotine mediates different types of anxiety Eur. J. Pharmacol. 393 2000 231 236
12. T.P. George, and S.S. O'Malley Current pharmacological treatments for nicotine dependence TIPS 25 2004 42 48
13. J.T. Hays, and J.O. Ebbert Bupropion for the treatment of tobacco dependence. Guidelines for balancing risks and benefits CNS Drugs 17 2003 71 83
14. M.A. Herztberg, S.D. Moore, M.E. Feldman, and J.C. Beckham A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder J. Clin. Psychopharmacol. 21 2001 94 98
15. K.J. Holm, and C.M. Spencer Bupropion: a review of its use in the management of smoking cessation Drugs 59 2000 41007 41024
16. A. Holmes, and R.J. Rodgers Prior exposure to the elevated plus-maze sensitizes mice to acute behavioral effects of fluoxetine and phenelzine Eur. J. Pharmacol. 459 2003 221 230
17. J.R. Hughes, L.F. Stead, and T. Lancaster Anxiolytics and antidepressants for smoking cessation The Cochrane Library, Issue 2 2000 Update Software Oxford
18. D.E. Jorenby, S.J. Leischow, M.A. Nides, S.I. Rennard, J.A. Johnston, A.R. Hughes, S.S. Smith, J.L. Muramoto, D.M. Daughton, K. Doan, M.C. Fiore, and T.B. Baker A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation N. Engl. J. Med. 340 1999 685 691
19. P.J. Kenny, and A. Markou Neurobiology of the nicotine withdrawal syndrome Pharmacol. Biochem. Behav. 70 2001 531 549
20. V. Klimek, G. Nowak, and A. Czyrak Central effects of repeated treatment with bupropion Pol. J. Pharmacol. Pharm. 37 1985 243 252
21. J.R. Lake, A.L. Montellano, S.E. Presley, R.L. Meyer-Paal, B.A. Perales, M. Oliver, and D.H. Malin Acute-bupropion dose-dependently reduces nicotine abstinence syndrome in the rat Abstr.-Soc. Neurosci. 27 2001 15 (Program No 572)
22. C. Lerman, D. Roth, V. Kaufmann, J. Audrain, L. Hawk, A. Liu, R. Niaura, and L. Epstein Mediating mechanisms for the impact of bupropion in smoking cessation treatment Drug Alcohol Depend. 67 2002 219 223
23. S.X. Li, K.W. Perry, and D.T. Wong Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats Neuropharmacology 42 2002 181 190
24. J.H. Meyer, V.S. Goulding, A.A. Wilson, D. Hussey, B.K. Christensen, and S. Houle Bupropion occupancy of the dopamine transporter is low during clinical treatment Psychopharmacology 163 2002 102 105
25. M.P. Muley, M.A. Joshi, and M.S. Manekar Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice J. Pharmacol. 36 1984 208 210
26. T. Nakagawa, K. Ukai, T. Ohyama, Y. Gomita, and H. Okamura Effects of dopaminergic agents on reversal of reserpine-induced impairment in conditioned avoidance response in rats Pharmacol. Biochem. Behav. 58 1997 829 836
27. S. Pellow, and S.E. File Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat Pharmacol. Biochem. Behav. 24 1986 525 529
28. R.J. Rodgers, and J.C. Cole Influence of social isolation, gender, strain and prior novelty on plus-maze behaviour in mice Physiol. Behav. 54 1993 729 736
29. R.J. Rodgers, and J.C. Cole The elevated plus-maze: pharmacology, methodology and ethology S.J. Cooper C.A. Hendrie Ethology and Psychopharmacology 1994 Wiley Chichester 9 44
30. R.J. Rodgers, N.J.T. Johnson, J. Carr, and T.P. Hodgson Resistance of experientially-induced changes in murine plus-maze behaviour to altered retest conditions Behav. Brain Res. 86 1997 71 77
31. R.J. Rodgers, J. Haller, A. Holmes, J. Halasz, T.J. Walton, and P.F. Brain Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice Physiol. Behav. 68 1999 47 53
32. A.L. Rush, M.H. Trivedi, S.R. Batey, R.M.J. Donahue, T.J. Carmody, T.L. Houser, C. Bolden-Watson, and A. Metz Anxiolysis associated with antidepressant response to bupropion sustained release or sertraline Int. J. Neuropsychopharmacol. 3 Suppl. 1 2000 S235
33. A.J. Rush, M.H. Trivedi, T.J. Carmody, R.M.J. Donahue, T.L. Houser, C. Bolden-Watson, S.R. Batey, J.A. Ascher, and A. Metz Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline Neuropsychopharmacology 25 2001 131 138
34. S. Shiffman, J.A. Johnston, M. Khayrallah, C.A. Elash, C.J. Gwaltney, J.A. Paty, M. Gnys, G. Evoniuk, and J. DeVeaugh-Geiss The effect of bupropion on nicotine craving and withdrawal Psychopharmacology 148 2000 33 40
35. M. Shoaib, N. Sidhpura, and S. Shafait Investigating the actions of bupropion on dependence-related effects of nicotine in rats Psychopharmacology 165 2003 405 412
36. J.E. Slemmer, B.R. Martin, and M.I. Damaj Bupropion is a nicotinic antagonist J. Pharmacol. Exp. Ther. 295 2000 321 327
37. F.E. Soroko, N.B. Mehta, R.A. Maxwell, R.M. Ferris, and D.H. Schroeder Bupropion hydrochloride (±) (-t-butylamino-3-chloropropiophenone HCL): a novel antidepressant agent J. Pharm. Pharmacol. 29 1977 767 770
38. R. Suckow, T. Smith, A. Perumal, and T. Cooper Pharmacokinetics of bupropion and metabolites in plasma of rats, mice and guinea pigs Drug Metab. Dispos. 14 1986 692 697
39. A.J. Tomarken, G.S. Dichter, C. Freid, S. Addington, and R.C. Shelton Assessing the effects of bupropion SR on mood dimensions of depression J. Affect Dis. 78 2004 235 241
40. P.M. Wall, and C. Messier Ethological confirmatory factor analysis of anxiety-like behaviour in the murine elevated plus-maze Behav. Brain Res. 114 2000 199 212
41. T.E. Wilens, T.J. Spencer, J. Biederman, K. Girard, R. Doyle, J. Prince, D. Polisner, R. Solhkhah, S. Comeau, M.C. Monuteaux, and A. Parekh A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults Am. J. Psychiatry 158 2001 282 288
42. R. Young, and R.A. Glennon Nicotine and bupropion share a similar discriminative stimulus effect Eur. J. Pharmacol. 443 2002 113 118
43. M.R. Zarrindast, and F. Abolfathi-Araghi Effects of bupropion on core body temperature of mice Psychopharmacology 106 1992 248 252
44. M.R. Zarrindast, and T. Hosseini-Nia Anorectic and behavioural effects of bupropion Gen. Pharmacol. 19 1988 201 204
45. M.R. Zarrindast, Y. Khajenabi, and M.H. Pourgholami Bupropion-induced climbing through D-1 and D-2 dopamine receptor activation Med. J. Islam. Repub. Iran 6 1993 285 289
46. M.R. Zarrindast, M.R. Hodjati, A. Pejhan, and E. Soleimannejad Bupropion induces sniffing: a possible dopaminergic mechanism Eur. Neuropsychopharmacol. 6 1996 299 303
47. M. Zarrindast, H. Momayoun, A. Babaie, A. Etminani, and B. Gharib Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice Eur. J. Pharmacol. 407 2000 145 158